Amgen heart failure drug deal is good news — but little more — for Cytokinetics San Francisco Business Times (blog) Thousand Oaks-based Amgen, meanwhile, received U.S. commercial rights to Servier's chronic heart failure drug ivabradine, which is approved in Europe, and an exclusive option to develop and commercialize Servier's Phase II heart failure drug S-38844 in ... |
